AOTI, Inc. (LSE:AOTI) is one of a small group of US-headquartered medical technology companies that have chosen London's growth market for their listing, and that choice makes it an unusual member of the FTSE AIM All Share Index. Its commercial-stage therapy for chronic wounds, its dependence on reimbursement and its clinical evidence base define how the business is viewed.

What the company does

AOTI develops and sells a home-based therapy for chronic wounds that uses topically applied oxygen. Its system, marketed under the TWO2 name, delivers cyclical pressurised oxygen directly to a wound through a single-use device that patients can use at home. The company has focused on hard-to-heal wounds such as diabetic foot ulcers, venous leg ulcers and pressure ulcers, conditions that place a heavy and growing burden on health systems and that often lead to serious complications, including amputation, when they fail to heal.

The group's main market is the United States, where reimbursement from public and private payers is central to adoption. It has also pursued sales in other territories, including the United Kingdom, through a mix of direct and distributor arrangements. A key part of its pitch has been clinical evidence, including randomised controlled trial data, which it uses to support both clinician adoption and reimbursement discussions.

Latest developments

AOTI's newsflow typically covers trading statements, interim and full-year results, changes in reimbursement status and updates on commercial expansion. Because the business depends heavily on payer coverage and clinician uptake, announcements touching on those areas tend to be the most significant for how the shares are viewed. New clinical publications and distribution agreements in additional markets are further recurring themes as the company seeks to broaden access to its therapy.

Financial and dividend picture

As a growth-stage medical device company, AOTI's financial story is centred on revenue growth, gross margin and progress towards sustained profitability rather than shareholder income. Revenue, cash, operating costs and any borrowings are the key elements of its accounts. Companies at this stage typically prioritise reinvestment in sales capacity and evidence generation over dividends, and the board's capital allocation priorities reflect that emphasis on building commercial scale.

Sector and index context

The FTSE AIM All Share Index captures a broad spread of smaller and growth companies, with healthcare and life sciences forming a meaningful segment alongside mining, energy, technology and financial services. Within that group, AOTI stands out as a commercial-stage device business rather than a pre-revenue drug developer. Wound care is a large and established market, but it is competitive, with advanced dressings, negative pressure systems and other therapies vying for clinician attention and payer budgets. Sentiment towards AIM-listed healthcare stocks has also been influenced by wider factors such as liquidity on the junior market and investor appetite for smaller companies.

Key risks

The principal risks include changes to reimbursement policy in the United States, slower than expected adoption by clinicians, competition from alternative wound therapies, and execution risk as the company expands its sales footprint. As a US company quoted in London, it may also be affected by currency movements and by the relatively limited trading liquidity common to many AIM stocks. Regulatory requirements for medical devices add a further layer of compliance risk.

What to watch next

Key items to monitor include the next trading update or results statement, any developments on payer coverage, new clinical data or publications, distribution agreements in new markets, and commentary on the path to profitability. The extent to which AOTI (LSE:AOTI) can widen reimbursement and clinician adoption will be central to its progress.